My understanding is that there are multiple pathways anthracyclines target that produce cardiotoxicity, from mitochondrial direct to indirect. We really need to know what the cardio MoA for Bisantrene is so that our targets can be a little more real. If Bis MoA was targeting a similar pathway in Ara-C, that would be a very big de-risking event for the upcoming trial. Probably already the most derisked oncology drug on the planet.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080657/pdf/fcvm-07-00035.pdf
Pillar 1 - FTO (new thread), page-2885
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.040(2.42%) |
Mkt cap ! $274.2M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.70 | $1.60 | $229.6K | 139.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 129 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 2839 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |